Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.385 USD | +2.38% | +2.94% | +6.73% |
Financials (USD)
Sales 2024 * | 204K | Sales 2025 * | 11.85M | Capitalization | 183M |
---|---|---|---|---|---|
Net income 2024 * | -72M | Net income 2025 * | -62M | EV / Sales 2024 * | 896 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 15.4 x |
P/E ratio 2024 * |
-2.45
x | P/E ratio 2025 * |
-3.52
x | Employees | 24 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.15% |
Latest transcript on Outlook Therapeutics, Inc.
1 day | -0.12% | ||
1 week | -1.21% | ||
Current month | -31.41% | ||
1 month | -3.76% | ||
3 months | -5.84% | ||
6 months | -22.74% | ||
Current year | +3.93% |
Managers | Title | Age | Since |
---|---|---|---|
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Lawrence Kenyon
DFI | Director of Finance/CFO | 58 | 15-09-14 |
Surendra Sharma
CTO | Chief Tech/Sci/R&D Officer | - | 23-01-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Randy Thurman
CHM | Chairman | 74 | 18-04-12 |
Kurt Hilzinger
BRD | Director/Board Member | 63 | 15-12-10 |
C. Trenary
CEO | Chief Executive Officer | 66 | 21-07-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 9 M€ | +5.51% | - | |
0.00% | 147 M€ | +4.88% | - | |
0.00% | 18 M€ | +3.26% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 8.41 | +2.69% | 106 031 |
24-04-25 | 8.19 | -0.12% | 150,771 |
24-04-24 | 8.2 | 0.00% | 339,980 |
24-04-23 | 8.2 | +1.36% | 151,657 |
24-04-22 | 8.09 | -0.98% | 210,765 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.93% | 183M | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+47.64% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- OTLK Stock